The numerical survival benefit versus Keytruda underperform’s Merck’s phase 3 study, but there’s a possible reason for that.

In paying $5.5bn for immediate rights to three Daiichi Sankyo assets Merck & Co has made its biggest bet on ADCs to date.

But late-breaking data raise questions about lack of a dose response.

However, lack of meaningful efficacy in Tropion-Lung01 suggests that datopotamab deruxtecan might be restricted to a histology-defined NSCLC subgroup.

Rybrevant underwhelms in Mariposa, handing a possible advantage back to AstraZeneca’s Tagrisso.

And first data with a low dose are particularly unimpressive.